Brain atrophy in Alzheimer's disease and aging
Thanks to its safety and accessibility, magnetic resonance imaging (MRI) is extensively used
in clinical routine and research field, largely contributing to our understanding of the …
in clinical routine and research field, largely contributing to our understanding of the …
Diagnosis and treatment for mild cognitive impairment: a systematic review of clinical practice guidelines and consensus statements
YX Chen, N Liang, XL Li, SH Yang, YP Wang… - Frontiers in …, 2021 - frontiersin.org
Background: Mild cognitive impairment (MCI) is an important stage between the normal
cognitive decline of aging and dementia. The aim of this study was to compare and …
cognitive decline of aging and dementia. The aim of this study was to compare and …
Predicting Alzheimer's disease progression using multi-modal deep learning approach
Alzheimer's disease (AD) is a progressive neurodegenerative condition marked by a decline
in cognitive functions with no validated disease modifying treatment. It is critical for timely …
in cognitive functions with no validated disease modifying treatment. It is critical for timely …
Multimodal multitask deep learning model for Alzheimer's disease progression detection based on time series data
Early prediction of Alzheimer's disease (AD) is crucial for delaying its progression. As a
chronic disease, ignoring the temporal dimension of AD data affects the performance of a …
chronic disease, ignoring the temporal dimension of AD data affects the performance of a …
Hierarchical feature representation and multimodal fusion with deep learning for AD/MCI diagnosis
For the last decade, it has been shown that neuroimaging can be a potential tool for the
diagnosis of Alzheimer's Disease (AD) and its prodromal stage, Mild Cognitive Impairment …
diagnosis of Alzheimer's Disease (AD) and its prodromal stage, Mild Cognitive Impairment …
Neuroimaging biomarkers for Alzheimer's disease
F Márquez, MA Yassa - Molecular neurodegeneration, 2019 - Springer
Currently, over five million Americans suffer with Alzheimer's disease (AD). In the absence of
a cure, this number could increase to 13.8 million by 2050. A critical goal of biomedical …
a cure, this number could increase to 13.8 million by 2050. A critical goal of biomedical …
Neurons, nose, and neurodegenerative diseases: olfactory function and cognitive impairment
I Fatuzzo, GF Niccolini, F Zoccali, L Cavalcanti… - International Journal of …, 2023 - mdpi.com
Olfactory capacity declines with aging, but increasing evidence shows that smell dysfunction
is one of the early signs of prodromal neurodegenerative diseases such as Alzheimer's and …
is one of the early signs of prodromal neurodegenerative diseases such as Alzheimer's and …
Two-stage deep learning model for Alzheimer's disease detection and prediction of the mild cognitive impairment time
Alzheimer's disease (AD) is an irreversible neurodegenerative disease characterized by
thinking, behavioral and memory impairments. Early prediction of conversion from mild …
thinking, behavioral and memory impairments. Early prediction of conversion from mild …
Latent feature representation with stacked auto-encoder for AD/MCI diagnosis
Recently, there have been great interests for computer-aided diagnosis of Alzheimer's
disease (AD) and its prodromal stage, mild cognitive impairment (MCI). Unlike the previous …
disease (AD) and its prodromal stage, mild cognitive impairment (MCI). Unlike the previous …
The Trail Making Test: Association with other neuropsychological measures and normative values for adults aged 55 years and older from a Spanish-speaking …
J Llinàs-Reglà, J Vilalta-Franch… - …, 2017 - journals.sagepub.com
The Trail Making Test (TMT) is used as an indicator of visual scanning, graphomotor speed,
and executive function. The aim of this study was to examine the TMT relationships with …
and executive function. The aim of this study was to examine the TMT relationships with …